BioSante Pharmaceuticals, Inc. (BPAX)

[keekee]

This was fairly predictable...both on the charts and in the statistics. The stock was trading at essentially its cash value, while biotechs generally trade at Perceived Future Value. The PPS did not price in the impending possible approval, and completely wrote off the Libigel and 17 other product trials. That's why I believe the stock is still headed to $2. Short action brought it down, most real owners (who actually know the company) held their shares. This stock is going much higher when you even price in half its perceived value. In here till it's over

ALSO tax-loss liquidation probably aided the shorts, but I am sure very many of the owners are back in or clamouring to reenter